Design and results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis | Dr Ruben Mesa at Annual Meeting 2015

Design and results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis | Dr Ruben Mesa at Annual Meeting 2015

User Photo
EMJ

5 years
882 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay